PRIMARY HYPEROXALURIA TYPE 1 (PH1)

Clinical trials for PRIMARY HYPEROXALURIA TYPE 1 (PH1) explained in plain language.

Never miss a new study

Get alerted when new PRIMARY HYPEROXALURIA TYPE 1 (PH1) trials appear

Sign up with your email to follow new studies for PRIMARY HYPEROXALURIA TYPE 1 (PH1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Gene therapy trial aims to tame rare kidney stone disease

Disease control Recruiting now

This early-stage study tests a new gene therapy called ABO-101 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes painful kidney stones and kidney damage. The trial will first give a single dose to adults to find the safest amount, then test …

Matched conditions: PRIMARY HYPEROXALURIA TYPE 1 (PH1)

Phase: PHASE1, PHASE2 • Sponsor: Arbor Biotechnologies • Aim: Disease control

Last updated May 04, 2026 03:10 UTC

PRIMARY HYPEROXALURIA TYPE 1 (PH1)

Get alerted when new PRIMARY HYPEROXALURIA TYPE 1 (PH1) trials appear

Gene therapy trial aims to tame rare kidney stone disease